Mogamilizumab Prior to HSCT and GVHD in Patients With CTCL

This case series describes the occurrence of graft-vs-host-disease (GVHD) in patients with cutaneous T-cell lymphomas (CTCLs) treated with the CC chemokine receptor 4 (CCR4) antibody mogalizumab prior to allogeneic hematopoietic stem cell transplantation (HSCT).

https://ift.tt/2GIcSV3